Horwitz, Steven Michael

Publications

Sort by

Co-Author Network

selected publications

Cancer worry and empathy moderate the effect of a survivorship-focused intervention on quality of life. Psycho-oncology. 2020 Academic Article GET IT
Times cited: 15
C-C chemokine receptor 4 expression in CD8+ cutaneous T-cell lymphomas and lymphoproliferative disorders, and its implications for diagnosis and treatment. Histopathology. 2019 Academic Article GET IT
Times cited: 11
Fear of cancer recurrence in lymphoma survivors: A descriptive study. Journal of psychosocial oncology. 2019 Academic Article GET IT
Times cited: 18
Level of evidence used in recommendations by the National Comprehensive Cancer Network (NCCN) guidelines beyond Food and Drug Administration approvals. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Academic Article GET IT
Times cited: 16
Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center. Journal of the American Academy of Dermatology. 2019 Academic Article GET IT
Times cited: 38
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry. Acta haematologica. 2019 Academic Article GET IT
Times cited: 40
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. Blood. 2019 Academic Article GET IT
Times cited: 103
Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood cancer journal. 2019 Academic Article GET IT
Times cited: 110
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. Leukemia & lymphoma. 2019 Article GET IT
Times cited: 32
Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry. American journal of hematology. 2019 Academic Article GET IT
Times cited: 37
Targeting CD47 in Sézary syndrome with SIRPαFc. Blood advances. 2019 Academic Article GET IT
Times cited: 96
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Annals of oncology : official journal of the European Society for Medical Oncology. 2019 Article GET IT
Times cited: 20
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. Blood. 2019 Academic Article GET IT
Times cited: 59
Mycosis fungoides, Psoriasis und PD-1-Inhibitoren - neuer Aspekt einer bekannten Assoziation. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2019 Article GET IT
Times cited: 1
Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Academic Article GET IT
Times cited: 138
2019 NCCN Consensus Guidelines on the Diagnosis and Treatment of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL). Aesthetic surgery journal. 2019 Information Resource GET IT
Times cited: 282
Role of imaging in low-grade cutaneous B-cell lymphoma presenting in the skin. Journal of the American Academy of Dermatology. 2019 Academic Article GET IT
Times cited: 19
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer. 2019 Academic Article GET IT
Times cited: 144
Baseline and interim functional imaging with PET effectively risk stratifies patients with peripheral T-cell lymphoma. Blood advances. 2019 Academic Article GET IT
Times cited: 48
Revised Adult T-Cell Leukemia-Lymphoma International Consensus Meeting Report. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2019 Information Resource GET IT
Times cited: 237
Immunotherapy in mycosis fungoides: opening night or dress rehearsal?. Leukemia & lymphoma. 2019 Article GET IT
A new target in CTCL: treating the skin, blood, and lymph nodes. Clinical advances in hematology & oncology : H&O. 2019 Article GET IT
Angioimmunoblastic T-Cell Lymphoma. Cancer treatment and research. 2019 Academic Article GET IT
Times cited: 29
Mogamulizumab versus investigator's choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma. Haematologica. 2018 Academic Article GET IT
Times cited: 68
Mycosis fungoides, Psoriasis and Anti-PD-1 - A New Aspect of Known Associations. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2018 Article GET IT
Times cited: 4
Breast implant-associated anaplastic large cell lymphoma: Clinical and imaging findings at a large US cancer center. The breast journal. 2018 Academic Article GET IT
Times cited: 18
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet (London, England). 2018 Academic Article GET IT
Times cited: 680
Novel Immunotherapies for T Cell Lymphoma and Leukemia. Current hematologic malignancy reports. 2018 Information Resource GET IT
Times cited: 31
Cutaneous T-cell lymphoma (CTCL), rare subtypes: five case presentations and review of the literature. Chinese clinical oncology. 2018 Article GET IT
Times cited: 29
Treatment of Rosai-Dorfman disease with oral bexarotene: a case series. The Journal of dermatological treatment. 2018 Article GET IT
Times cited: 3
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. American journal of hematology. 2018 Academic Article GET IT
Times cited: 59
Efficacy of a survivorship-focused consultation versus a time-controlled rehabilitation consultation in patients with lymphoma: A cluster randomized controlled trial. Cancer. 2018 Academic Article GET IT
Times cited: 15
How I treat breast implant-associated anaplastic large cell lymphoma. Blood. 2018 Article GET IT
Times cited: 70
Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study. American journal of hematology. 2018 Academic Article GET IT
Times cited: 38
Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. The Lancet. Oncology. 2018 Academic Article GET IT
Times cited: 595
T-cell receptor-δ expression and γδ+ T-cell infiltrates in primary cutaneous γδ T-cell lymphoma and other cutaneous T-cell lymphoproliferative disorders. Histopathology. 2018 Academic Article GET IT
Times cited: 34
Peripheral T-cell lymphoma - are we making progress?. Best practice & research. Clinical haematology. 2018 Information Resource GET IT
Times cited: 12
Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile. Cancer immunology research. 2018 Academic Article GET IT
Times cited: 95
Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma. Blood advances. 2018 Academic Article GET IT
Times cited: 19
Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. British journal of haematology. 2018 Academic Article GET IT
Times cited: 63
The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project. Haematologica. 2018 Academic Article GET IT
Times cited: 150
Adult-Onset Still's Disease and Macrophage-Activating Syndrome Progressing to Lymphoma: A Clinical Pathology Conference Held by the Division of Rheumatology at Hospital for Special Surgery. HSS journal : the musculoskeletal journal of Hospital for Special Surgery. 2018 Academic Article GET IT
Times cited: 6
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas. Blood. 2018 Academic Article GET IT
Times cited: 61
Association of Breast Implants With Anaplastic Large-Cell Lymphoma. JAMA oncology. 2018 Article GET IT
Times cited: 6
NCCN Guidelines Insights: T-Cell Lymphomas, Version 2.2018. Journal of the National Comprehensive Cancer Network : JNCCN. 2018 Information Resource GET IT
Times cited: 56
Syngeneic hematopoietic stem cell transplantation from HTLV-1 seropositive twin for adult T-cell leukemia-lymphoma. Bone marrow transplantation. 2018 Article GET IT
Times cited: 3
Activity of the PI3K-δ,γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma. Blood. 2017 Academic Article GET IT
Times cited: 287
Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies. Blood. 2017 Academic Article GET IT
Times cited: 230
Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study. Journal of the American Academy of Dermatology. 2017 Academic Article GET IT
Times cited: 2
Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium. Annals of oncology : official journal of the European Society for Medical Oncology. 2017 Academic Article GET IT
Times cited: 120
Erratum to: Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. Journal of hematology & oncology. 2017 Article GET IT
Times cited: 7
Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood. 2017 Academic Article GET IT
Times cited: 121
Clinical Outcome and Prognosis of Young Patients with Mycosis Fungoides. Pediatric dermatology. 2017 Academic Article GET IT
Times cited: 40
Adult T-Cell Leukemia/Lymphoma. Journal of oncology practice. 2017 Information Resource GET IT
Times cited: 66
Primary cutaneous marginal zone lymphoma with leptomeningeal involvement and a durable response to rituximab. JAAD case reports. 2017 Article GET IT
Times cited: 2
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet (London, England). 2017 Academic Article GET IT
Times cited: 559
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 24
Romidepsin is effective and well tolerated in older patients with peripheral T-cell lymphoma: analysis of two phase II trials. Leukemia & lymphoma. 2017 Academic Article GET IT
Times cited: 21
Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2017 Academic Article GET IT
Times cited: 23
Highlights in lymphoma from the 2016 American Society of Hematology annual meeting and exposition: Commentary. Clinical advances in hematology & oncology : H&O. 2017 Conference Paper GET IT
The Genetic Basis of Hepatosplenic T-cell Lymphoma. Cancer discovery. 2017 Academic Article GET IT
Times cited: 189
Systemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?. Expert review of hematology. 2016 Information Resource GET IT
Times cited: 16
Responses to romidepsin by line of therapy in patients with relapsed or refractory peripheral T-cell lymphoma. Cancer medicine. 2016 Academic Article GET IT
Times cited: 19
Lenalidomide in Adult T-Cell Leukemia/Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2016 Editorial Article GET IT
Times cited: 3
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice. Cancer cell. 2016 Academic Article GET IT
Times cited: 212
Diffuse Large B-Cell Lymphoma Version 1.2016. Journal of the National Comprehensive Cancer Network : JNCCN. 2016 Academic Article GET IT
Times cited: 81
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2015 Academic Article GET IT
Times cited: 396
Therapy for Peripheral T-Cell Lymphomas: Where We Are and Where We Hope to Be. Oncology (Williston Park, N.Y.). 2015 Article GET IT
mTOR inhibition in T-cell lymphoma: a path(way) forward. Blood. 2015 Article GET IT
Times cited: 3
Current and novel treatment options for peripheral T-cell lymphoma. Clinical advances in hematology & oncology : H&O. 2015 Article GET IT
Times cited: 1
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. Journal of the National Comprehensive Cancer Network : JNCCN. 2015 Information Resource GET IT
Times cited: 58
Zebras and hen's teeth: recognition and management of rare T and NK lymphomas. Hematology. American Society of Hematology. Education Program. 2015 Academic Article GET IT
Times cited: 3
Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma. Biomarker research. 2014 Academic Article GET IT
Times cited: 28
Targeted mutational profiling of peripheral T-cell lymphoma not otherwise specified highlights new mechanisms in a heterogeneous pathogenesis. Leukemia. 2014 Article GET IT
Times cited: 72
Non-Hodgkin's lymphomas, version 4.2014. Journal of the National Comprehensive Cancer Network : JNCCN. 2014 Information Resource GET IT
Times cited: 107
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 161
Non-Hodgkin's lymphomas, version 2.2014. Journal of the National Comprehensive Cancer Network : JNCCN. 2014 Information Resource GET IT
Times cited: 62
Commentary. Clinical advances in hematology & oncology : H&O. 2014 Academic Article GET IT
Highlights in T-cell lymphoma From the 2013 American Society of Hematology Annual Meeting and Exposition: commentary. Clinical advances in hematology & oncology : H&O. 2014 Academic Article GET IT
Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma. Annals of oncology : official journal of the European Society for Medical Oncology. 2013 Academic Article GET IT
Times cited: 29
Romidepsin for previously treated patients with peripheral or aggressive T-cell lymphomas. Clinical advances in hematology & oncology : H&O. 2012 Information Resource GET IT
Highlights in T-cell lymphoma from the 2011 American Society of Hematology Annual Meeting and Exposition. Clinical advances in hematology & oncology : H&O. 2012 Conference Paper GET IT
T-cell lymphomas in South america and europe. Revista brasileira de hematologia e hemoterapia. 2012 Academic Article GET IT
Times cited: 54
EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood. 2011 Information Resource GET IT
Times cited: 392
Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Information Resource GET IT
Times cited: 623
Inter-rater reliability of the Pediatric Transplant Rating Instrument (P-TRI): challenges to reliably identifying adherence risk factors during pediatric pre-transplant evaluations. Pediatric transplantation. 2011 Academic Article GET IT
Times cited: 17
Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?. Current oncology reports. 2010 Information Resource GET IT
Times cited: 8
A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score. Cancer. 2010 Academic Article GET IT
Times cited: 62
T-cell lymphoma: Where we are going. Clinical Advances in Hematology and Oncology. 2010 Article
A multi-institutional experience of autologous stem cell transplantation in North American patients with human T-cell lymphotropic virus type-1 adult T-cell leukemia/lymphoma suggests ineffective salvage of relapsed patients. Leukemia & lymphoma. 2009 Article GET IT
Times cited: 22
T-cell lymphomas. Clinical advances in hematology & oncology : H&O. 2009 Academic Article GET IT
Times cited: 1
Rare T-cell lymphomas. Cancer treatment and research. 2008 Information Resource GET IT
Times cited: 1
Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients. Archives of dermatology. 2004 Academic Article GET IT
Times cited: 44
Gemcitabine is active in relapsed Hodgkin's disease. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Article GET IT
Times cited: 19
Three-dimensional computed tomography studies of the tendons of the foot and ankle. Journal of digital imaging. 1992 Academic Article GET IT
Times cited: 13

more ...

less ...

Background

education and training

M.D., Case Western Reserve University School of Medicine 1993
B.A., University of Michigan 1989

Contact

full name

Steven Michael Horwitz

VIVO Weill Cornell Medical College

Steven Michael Horwitz Professor of Medicine

Publications

selected publications

Background

education and training

Contact

full name

Phone

Publications

selected publications

Background

education and training

Contact

full name